Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.03, Bloomberg Earnings reports. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the company posted ($0.66) EPS. Bellicum Pharmaceuticals’s revenue was up 18.2% on a year-over-year basis.

Shares of Bellicum Pharmaceuticals (BLCM) traded down $0.30 during mid-day trading on Tuesday, hitting $9.75. 266,802 shares of the stock traded hands, compared to its average volume of 381,851. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.22. Bellicum Pharmaceuticals has a 52 week low of $7.41 and a 52 week high of $23.11.

TRADEMARK VIOLATION WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/07/bellicum-pharmaceuticals-inc-blcm-issues-quarterly-earnings-results.html.

BLCM has been the subject of a number of research analyst reports. BidaskClub lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. set a $18.00 target price on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and set a $16.00 target price (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 11th. Finally, Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $26.20.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.